Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by barcodewhizon Feb 01, 2018 12:39am
532 Views
Post# 27476676

just re listened to the webcast

just re listened to the webcast

At some point,  this preponderance of evidence that they have been compiling is going to reach a tipping point with scientists / physicians and ultimately  market  participants.....  Whether its the result of further compelling Allstrom data, or finally getting the clarity and peer review of the MOA....   its hard to say....or maybe its going to take the 26 week or 52 week data itself.....   But what you hear them saying more and more is that they may have actually cracked the core of Fibrosis with their molecules novel pathway / receptor action.   I found it extremly compelling to hear these KOL's speak to the novel nature of the compound and its potential.

If Prometic has somehow stumbled on a suite of molecules that truly addresses the core of Fibrosis,   and can actually not only halt fibrotic activity but actual reduce, heal and rebuild healthly tissue across organs....then either Industry or Wall Street will step up and make a bet.

 Any of you that have looked John Moran in the eyes knows thats what he has been saying all along....  

Feels to me that they might finally be finding enough believers.... both amongst researchers, industry and Investment Banks.    And that may be exactly what we are beginning to see play out in the stock.

Still a ways to go to have this all vetted out,  but with the MOA Peer review and more data now only a couple weeks away... the frying pan is heating up... and that may be exactly what we are seeing reflected in the stock.

The obsession around cash and the balance sheet will be a distant memory very shortly despite the best efforts of those who are betting otherwise.....   think Eddy Murphy  in Trading Places ...  
Bullboard Posts